Ovarian Cancer, Version 3.2012

Restricted access

These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See “Updates” in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

  • 1

    SiegelRNaishadhamDJemalA. Cancer statistics, 2012. CA Cancer J Clin2012;62:1029.

  • 2

    HowladerNNooneAKrapchoM. SEER Cancer Statistics Review 1975-2009 (Vintage 2009 Populations) based on November 2011 SEER data submission. Bethesda, MD: National Cancer Institute; 2012. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed October 12 2012.

    • Search Google Scholar
    • Export Citation
  • 3

    BuysSSPartridgeEBlackA. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA2011;305:22952303.

    • Search Google Scholar
    • Export Citation
  • 4

    SmithRACokkinidesVBrawleyOW. Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clinin press.

    • Search Google Scholar
    • Export Citation
  • 5

    Clarke-PearsonDL. Clinical practice. Screening for ovarian cancer. N Engl J Med2009;361:170177.

  • 6

    MenonUGentry-MaharajAHallettR. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol2009;10:327340.

    • Search Google Scholar
    • Export Citation
  • 7

    GilbertLBassoOSampalisJ. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol2012;13:285291.

    • Search Google Scholar
    • Export Citation
  • 8

    DrapkinRvon HorstenHHLinY. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res2005;65:21622169.

    • Search Google Scholar
    • Export Citation
  • 9

    NolenBVelikokhatnayaLMarrangoniA. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol2010;117:440445.

    • Search Google Scholar
    • Export Citation
  • 10

    CramerDWBastRCJrBergCD. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila)2011;4:365374.

    • Search Google Scholar
    • Export Citation
  • 11

    AndersonGLMcIntoshMWuL. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst2010;102:2638.

    • Search Google Scholar
    • Export Citation
  • 12

    JacobFMeierMCaduffR. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol2011;121:487491.

    • Search Google Scholar
    • Export Citation
  • 13

    MolinaREscuderoJMAugeJM. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol2011;32:10871095.

    • Search Google Scholar
    • Export Citation
  • 14

    Van GorpTCadronIDespierreE. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer2011;104:863870.

    • Search Google Scholar
    • Export Citation
  • 15

    MontagnanaMDaneseERuzzenenteO. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?Clin Chem Lab Med2011;49:521525.

    • Search Google Scholar
    • Export Citation
  • 16

    ImSSGordonANButtinBM. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol2005;105:3541.

  • 17

    ChiDSMusaFDaoF. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol2012;124:1014.

    • Search Google Scholar
    • Export Citation
  • 18

    SchorgeJOBradfordLSDel CarmenMG. Primary cytoreductive surgery for advanced ovarian cancer: is it the past, present, or future?Clin Adv Hematol Oncol2011;9:912918.

    • Search Google Scholar
    • Export Citation
  • 19

    FaderANRosePG. Role of surgery in ovarian carcinoma. J Clin Oncol2007;25:28732883.

  • 20

    DewdneySBRimelBJReinhartAJ. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol2010;119:1821.

    • Search Google Scholar
    • Export Citation
  • 21

    WhitneyCWSpirtosN. Gynecologic Oncology Group Surgical Procedures Manual. Philadelphia, PA: Gynecologic Oncology Group; 2009.

  • 22

    ElattarABryantAWinter-RoachBA. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev2011:CD007565.

    • Search Google Scholar
    • Export Citation
  • 23

    VergoteITropeCGAmantF. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med2010;363:943953.

  • 24

    VergoteITropeCGAmantF. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol2011;29:40764078.

    • Search Google Scholar
    • Export Citation
  • 25

    Rauh-HainJARodriguezNGrowdonWB. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol2012;19:959965.

    • Search Google Scholar
    • Export Citation
  • 26

    SchorgeJOGarrettLAGoodmanA. Cytoreductive surgery for advanced ovarian cancer: quo vadis?Oncology (Williston Park)2011;25:928934.

  • 27

    ChiDSBristowREArmstrongDKKarlanBY. Is the easier way ever the better way?J Clin Oncol2011;29:40734075.

  • 28

    RosePGNerenstoneSBradyMF. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med2004;351:24892497.

  • 29

    van der BurgMEvan LentMBuyseM. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med1995;332:629634.

    • Search Google Scholar
    • Export Citation
  • 30

    ColomboPEMourregotAFabbroM. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol2009;35:135143.

    • Search Google Scholar
    • Export Citation
  • 31

    HoskinsPJ. Which is the better surgical strategy for newly diagnosed epithelial ovarian cancer: primary or interval debulking?Curr Opin Oncol2011;23:501506.

    • Search Google Scholar
    • Export Citation
  • 32

    ChiDSEisenhauerELZivanovicO. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol2009;114:2631.

    • Search Google Scholar
    • Export Citation
  • 33

    ArmstrongDKBundyBWenzelL. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med2006;354:3443.

  • 34

    BurgerRABradyMFBookmanMA. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med2011;365:24732483.

  • 35

    PerrenTJSwartAMPfistererJ. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med2011;365:24842496.

  • 36

    CohnDEKimKHResnickKE. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol2011;29:12471251.

    • Search Google Scholar
    • Export Citation
  • 37

    HensleyML. Big costs for little gain in ovarian cancer. J Clin Oncol2011;29:12301232.

  • 38

    ParmarMKLedermannJAColomboN. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet2003;361:20992106.

    • Search Google Scholar
    • Export Citation
  • 39

    Mantia-SmaldoneGMEdwardsRPVladAM. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag Res2011;3:2538.

    • Search Google Scholar
    • Export Citation
  • 40

    GriffithsRWZeeYKEvansS. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer2011;21:5865.

    • Search Google Scholar
    • Export Citation
  • 41

    MarkmanM. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res2011;3:219225.

    • Search Google Scholar
    • Export Citation
  • 42

    ThigpenJTAghajanianCAAlbertsDS. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol2005;96:1018.

  • 43

    GordonANTondaMSunSRackoffW. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol2004;95:18.

    • Search Google Scholar
    • Export Citation
  • 44

    MutchDGOrlandoMGossT. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol2007;25:28112818.

    • Search Google Scholar
    • Export Citation
  • 45

    BurgerRASillMWMonkBJ. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol2007;25:51655171.

    • Search Google Scholar
    • Export Citation
  • 46

    TagawaTMorganRYenYMortimerJ. Ovarian cancer: opportunity for targeted therapy. J Oncol2012;2012:682480.

  • 47

    CannistraSAMatulonisUAPensonRT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol2007;25:51805186.

    • Search Google Scholar
    • Export Citation
  • 48

    AghajanianCBlankSVGoffBA. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol2012;30:20392045.

    • Search Google Scholar
    • Export Citation
  • 49

    Pujade-LauraineEHilpertFWeberB. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [abstract]. J Clin Oncol2012;30(Suppl 15):Abstract LBA5002.

    • Search Google Scholar
    • Export Citation
  • 50

    LedermannJHarterPGourleyC. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med2012;366:13821392.

    • Search Google Scholar
    • Export Citation
  • 51

    BuckanovichRJBergerRSellaA. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT) [abstract]. J Clin Oncol2011;29(Suppl 15):Abstract 5008.

    • Search Google Scholar
    • Export Citation
  • 52

    CernadasJRBrockowKRomanoA. General considerations on rapid desensitization for drug hypersensitivity—a consensus statement. Allergy2010;65:13571366.

    • Search Google Scholar
    • Export Citation
  • 53

    RomanoATorresMJCastellsM. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol2011;127:S6773.

  • 54

    CastellsMCTennantNMSloaneDE. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol2008;122:574580.

    • Search Google Scholar
    • Export Citation
  • 55

    DizonDSSabbatiniPJAghajanianC. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol2002;84:378382.

    • Search Google Scholar
    • Export Citation
  • 56

    SampsonHAMunoz-FurlongACampbellRL. Second symposium on the definition and management of anaphylaxis: summary report—second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med2006;47:373380.

    • Search Google Scholar
    • Export Citation
  • 57

    ManivannanVDeckerWWSteadLG. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int J Emerg Med2009;2:35.

    • Search Google Scholar
    • Export Citation
  • 58

    LenzHJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist2007;12:601609.

  • 59

    GabizonAA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest2001;19:424436.

    • Search Google Scholar
    • Export Citation
  • 60

    NavoMKunthurABadellML. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol2006;103:608613.

    • Search Google Scholar
    • Export Citation
  • 61

    MarkmanMZanottiKPetersonG. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol2003;21:46114614.

    • Search Google Scholar
    • Export Citation
  • 62

    VandenputIVan CalsterBCapoenA. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?Br J Cancer2009;101:244249.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 216 216 22
PDF Downloads 19 19 3
EPUB Downloads 0 0 0